Details of the Drug
General Information of Drug (ID: DM2QPHE)
Drug Name |
5-bromo-1H-indazole
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
5-bromo-1H-indazole; 5-Bromoindazole; 53857-57-1; 5-Bromo-2H-indazole; 1h-indazole, 5-bromo-; 465529-55-9; CHEMBL16425; 5-Bromo-1H-indazole, 97%; 5-brom-1h-indazol; MLS000088501; 5-bromoazaindole; 5-bromo-indazole; 5- Bromoindazole; 5-bromo-azaindole; 5-bromo-1hindazole; AC1LFXVY; 4-Nitrotrityl chloride; PubChem15628; 5-bromo-1 h-indazole; ACMC-209lal; 5-bromanyl-1H-indazole; 2H-Indazole, 5-bromo-; SCHEMBL5562; AC1Q1H9U; KSC269G3N; cid_761929; AMBZ0279; CTK1G9336; DTXSID50354020; HID1020; STVHMYNPQCLUNJ-UHFFFAOYSA-N; MolPort-029-084-055
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 197.03 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.9 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||